Лечение туберкулеза в современных условиях
Лечение туберкулеза в современных условиях
Синицын М.В., Калинина М.В., Белиловский Е.М. и др. Лечение туберкулеза в современных условиях. Терапевтический архив. 2020; 92 (8): 86–94. DOI: 10.26442/00403660.2020.08.000762
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Цель. Изучение современного состояния проблем проведения лечения больным туберкулезом на основе данных литературы и собственного опыта.
Материалы и методы. В Российской Федерации на фоне улучшения основных эпидемиологических показателей по туберкулезу продолжается увеличение числа и доли больных коинфекцией ВИЧ/туберкулез. В 2017 г. среди впервые выявленных больных туберкулезом 20,9% имели ВИЧ-инфекцию. Сочетание двух инфекций существенно затрудняет дальнейшее улучшение ситуации по туберкулезу, а появление устойчивых к лекарственным препаратам штаммов микобактерий туберкулеза (МБТ) иногда полностью нивелирует результаты химиотерапии. В статье описаны схемы современной химиотерапии туберкулеза с учетом коинфекции ВИЧ/туберкулез, а также множественной лекарственной устойчивости (МЛУ) в сочетании с методиками оперативного лечения, а также анализированы данные эпидемиологического мониторинга лечения 1115 впервые выявленных в 2017 г. в Москве больных туберкулезом, 360 больных туберкулезом с МЛУ МБТ (когорта 2013–2014 гг.), результаты лечения с применением новых схем химиотерапии туберкулеза (бедаквилин, линезолид, моксифлоксацин) у 36 больных, эффективность и безопасность хирургических методов у 192 пациентов.
Результаты. Применение новых индивидуализированных схем противотуберкулезной химиотерапии у больных коинфекцией ВИЧ/туберкулез с МЛУ МБТ позволило достоверно увеличить эффективность лечения. Доказано, что хирургическое вмешательство в сочетании с современными схемами химиотерапии у больных коинфекцией ВИЧ/туберкулез с МЛУ МБТ является эффективным и безопасным, способствует улучшению результатов лечения данной категории больных.
Заключение. Слияние двух глобальных проблем коинфекции ВИЧ/туберкулез и МЛУ МБТ значительно препятствует прекращению эпидемии туберкулеза в мире. В то же время успехи в разработке и внедрении новых противотуберкулезных препаратов и методов оперативного лечения создают надежду на существенный прогресс в разрешении этой ситуации.
Ключевые слова: туберкулез, ВИЧ-инфекция, коинфекция ВИЧ/туберкулез, широкая лекарственная устойчивость возбудителя, химиотерапия.
Materials and methods. In the Russian Federation, the number and proportion of patients with co-infection with HIV/tuberculosis continues to increase against the background of improvement in the main epidemiological indicants for tuberculosis. In 2017, 20.9% of newly diagnosed tuberculosis patients had HIV infection. The combination of the two infections significantly complicates the further improvement of the situation with tuberculosis, and the appearance of drug-resistant strains of Mycobacterium tuberculosis sometimes completely neutralizes the results of chemotherapy. The article describes the schemes of modern tuberculosis chemotherapy taking into account HIV/tuberculosis co-infection, as well as MDR in combination with surgical treatment methods, as well as analyzes the data of epidemiological monitoring of treatment of 1115 tuberculosis patients newly diagnosed in 2017 in Moscow, 360 tuberculosis patients with MDR MBT (cohort 2013–2014), the results of treatment with the use of new chemotherapy regimens for tuberculosis (bedaquiline, linezolid, moxifloxacin) in 36 patients, the effectiveness and safety of surgical methods in 192 patients.
Results. The application of new individualized anti-TB chemotherapy schedules in patients with HIV co-infection/tuberculosis with MDR-MBT has allowed to improve the treatment efficacy. The surgical intervention combined with modern chemotherapy regimens in patients with HIV/tuberculosis co-infection with MDR MBT has been proved to be effective and safe, contributes to the improving the results of treatment for this category of patients.
Conclusion. The confluence of two global problems of co-infection HIV/TB and MDR TB, significantly prevents from the end of the tuberculosis epidemic in the world. At the same time, advances in the development and implementation of new anti-TB drugs and surgical treatment methods give hope for significant progress for resolving this situation.
Keywords: tuberculosis, HIV infection, HIV/tuberculosis co-infection, multidrug-resistant tuberculosis, chemotherapy.
Материалы и методы. В Российской Федерации на фоне улучшения основных эпидемиологических показателей по туберкулезу продолжается увеличение числа и доли больных коинфекцией ВИЧ/туберкулез. В 2017 г. среди впервые выявленных больных туберкулезом 20,9% имели ВИЧ-инфекцию. Сочетание двух инфекций существенно затрудняет дальнейшее улучшение ситуации по туберкулезу, а появление устойчивых к лекарственным препаратам штаммов микобактерий туберкулеза (МБТ) иногда полностью нивелирует результаты химиотерапии. В статье описаны схемы современной химиотерапии туберкулеза с учетом коинфекции ВИЧ/туберкулез, а также множественной лекарственной устойчивости (МЛУ) в сочетании с методиками оперативного лечения, а также анализированы данные эпидемиологического мониторинга лечения 1115 впервые выявленных в 2017 г. в Москве больных туберкулезом, 360 больных туберкулезом с МЛУ МБТ (когорта 2013–2014 гг.), результаты лечения с применением новых схем химиотерапии туберкулеза (бедаквилин, линезолид, моксифлоксацин) у 36 больных, эффективность и безопасность хирургических методов у 192 пациентов.
Результаты. Применение новых индивидуализированных схем противотуберкулезной химиотерапии у больных коинфекцией ВИЧ/туберкулез с МЛУ МБТ позволило достоверно увеличить эффективность лечения. Доказано, что хирургическое вмешательство в сочетании с современными схемами химиотерапии у больных коинфекцией ВИЧ/туберкулез с МЛУ МБТ является эффективным и безопасным, способствует улучшению результатов лечения данной категории больных.
Заключение. Слияние двух глобальных проблем коинфекции ВИЧ/туберкулез и МЛУ МБТ значительно препятствует прекращению эпидемии туберкулеза в мире. В то же время успехи в разработке и внедрении новых противотуберкулезных препаратов и методов оперативного лечения создают надежду на существенный прогресс в разрешении этой ситуации.
Ключевые слова: туберкулез, ВИЧ-инфекция, коинфекция ВИЧ/туберкулез, широкая лекарственная устойчивость возбудителя, химиотерапия.
________________________________________________
Materials and methods. In the Russian Federation, the number and proportion of patients with co-infection with HIV/tuberculosis continues to increase against the background of improvement in the main epidemiological indicants for tuberculosis. In 2017, 20.9% of newly diagnosed tuberculosis patients had HIV infection. The combination of the two infections significantly complicates the further improvement of the situation with tuberculosis, and the appearance of drug-resistant strains of Mycobacterium tuberculosis sometimes completely neutralizes the results of chemotherapy. The article describes the schemes of modern tuberculosis chemotherapy taking into account HIV/tuberculosis co-infection, as well as MDR in combination with surgical treatment methods, as well as analyzes the data of epidemiological monitoring of treatment of 1115 tuberculosis patients newly diagnosed in 2017 in Moscow, 360 tuberculosis patients with MDR MBT (cohort 2013–2014), the results of treatment with the use of new chemotherapy regimens for tuberculosis (bedaquiline, linezolid, moxifloxacin) in 36 patients, the effectiveness and safety of surgical methods in 192 patients.
Results. The application of new individualized anti-TB chemotherapy schedules in patients with HIV co-infection/tuberculosis with MDR-MBT has allowed to improve the treatment efficacy. The surgical intervention combined with modern chemotherapy regimens in patients with HIV/tuberculosis co-infection with MDR MBT has been proved to be effective and safe, contributes to the improving the results of treatment for this category of patients.
Conclusion. The confluence of two global problems of co-infection HIV/TB and MDR TB, significantly prevents from the end of the tuberculosis epidemic in the world. At the same time, advances in the development and implementation of new anti-TB drugs and surgical treatment methods give hope for significant progress for resolving this situation.
Keywords: tuberculosis, HIV infection, HIV/tuberculosis co-infection, multidrug-resistant tuberculosis, chemotherapy.
Список литературы
1. World Health Organization. Global Tuberculosis Report 2019. Geneva, 2019. https://www.who.int/tb/publications/global_report/en/
2. Социально значимые заболевания населения России в 2018 году. Статистические материалы. Минздрав РФ, 2019 [Sotsial'no znachimye zabolevaniya naseleniya Rossii v 2018 godu (Statisticheskie materialy). Minzdrav RF, 2019 (In Russ.)]. https://www.rosminzdrav.ru/ministry/61/22/stranitsa-979/statisticheskie-i-informatsionnye-materialy/...
3. Эпидемиологическая ситуация по туберкулезу в России, 2018. ЦНИИОИЗ Минздрава РФ, 2019 [Epidemiologicheskaia situatsiia po tuberkulezu v Rossii, 2018. TsNIIOIZ Minzdrava RF, 2019 (In Russ.)]. https://mednet.ru/images/materials/CMT/2018_god_tuberkulez_
epidsituaciya.pdf
4. Противотуберкулезная работа в городе Москве. Аналитический обзор статистических показателей по туберкулезу, 2018. Под ред. Е.М. Богородской, В.И. Литвинова, Е.М. Белиловского. М.: МНПЦБТ, 2019 [Protivotuberkuleznaya rabota v gorode Moskve. Analiticheskii obzor statisticheskikh pokazatelei po tuberkulezu, 2018. Pod red. EM Bogorodskoi, VI Litvinova, EM Belilovskogo. Moscow: MNPTsBT, 2019 (In Russ.)].
5. ТБ/ВИЧ в Российской Федерации. Эпидемиология, особенности клинических проявлений и результаты лечения. Под ред. С.А. Стерликова. М.: РИО ЦНИИОИЗ, 2017 [TB/VICh v Rossiiskoi Federatsii. Epidemiologiya, osobennosti klinicheskikh proyavlenii i rezul'taty lecheniya. Pod red. SA Sterlikova. Moscow: RIO TsNIIOIZ, 2017 (In Russ.)].
6. Синицын М.В., Белиловский Е.М., Соколина И.А. и др. Внелегочные локализации туберкулеза у больных ВИЧ-инфекцией. Туберкулез и болезни легких. 2017;95(11):19-25. [Sinitsyn MV, Belilovsky EM, Sokolinа IA, et al. Extrapulmonary tuberculosis in HIV Patients. Tuberculosis and Lung Diseases. 2017;95(11):19-25 (In Russ.)]. doi: 10.21292/2075-1230-2017-95-11-19-25
7. Sacula A. Carlo Forlanini, inventor of artificial pneumothorax for treatment of pulmonary tuberculosis. Thorax. 1983;38:326-32. doi: 10.1136/thx.38.5.326
8. Jacobaeus HV. Ur die Moglichkeitdie Zystoskopie bei Untersuchung seroser Hohlungen anzuwenden. Munchener Medizinische Wochenschrift. 1910;57;2090-2.
9. Ghai SN. Extra pleural pneumonolysis with or without plombage in thoracoplasty failures: review of 21 cases. Indian J Tuberc. 1958;5(3):122-9.
10. Tiberi S, Torrico MM, Rahman A, et al. Managing severe tuberculosis and its sequelae: from intensive care to surgery and rehabilitation. J Brasileiro Pneumologia. 2019;45(2):e20180324. doi: 10.1590/1806-3713/e20180324
11. McDermott W, Muschenheim C, Hadley SD. Streptomycin in the treatment of tuberculosis in humans. J Clin Invest. 1947;26(6):1190.
12. Рабухин А.Е. Туберкулез органов дыхания у взрослых. М.: Медицина, 1976 [Rabukhin AE. Respiratory tuberculosis in adults. Moscow: Meditsina, 1976 (In Russ.)].
13. Хоменко А.Г. Химиотерапия туберкулеза легких. М.: Медицина, 1980 [Khomenko AG. Chemotherapy for pulmonary tuberculosis. Moscow: Meditsina, 1980 (In Russ.)].
14. Iseman MD, Sbarbaro JA. Short-course chemotherapy of tuberculosis. Hail Britannia (and friends)! Am Rev Respir Dis. 1991;(4 Pt 1):697-8. doi: 10.1164/ajrccm/143.4_Pt_1.697
15. Sensi P. History of the development of rifampin. Rev Infect Dis. 1983;5(Suppl. 3):S402-406. doi: 10.1093/clinids/5.supplement_3.s402
16. Styblo K. Recent advances in epidemiological research in tuberculosis. Advances in Tuberculosis Research. 1980;20:1-63.
17. Centers for Disease Control and Prevention (CDC). Pneumocystis pneumonia-Los Angeles. 1981. MMWR Morb Mortal Wkly Rep. 1996;45(34):729-33.
18. Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med. 1981;305(24):1425-31. doi: 10.1056/NEJM198112103052401
19. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;1:CD000171. doi: 10.1002/14651858.
CD000171.pub3
20. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2004;1:CD000171. doi: 10.1002/14651858.CD000171.pub2
21. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003;163(9):1009-21. doi: 10.1001/archinte.163.9.1009
22. Varghese GM, Janardhanan J, Ralph R, Abraham OC. The Twin Epidemics of Tuberculosis and HIV. Curr Infect Dis Rep. 2013;15:77-84. doi: 10.1007/s11908-012-0311-3
23. National Institute for Health and Clinical Excellence. Tuberculosis: Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London, 2016. https://www.nice.org.uk/guidance/ng33
24. Santin M, Muñoz L, Rigau D. Interferon-γ release assays for the diagnosis of tuberculosis and tuberculosis infection in HIV-infected adults: a systematic review and meta-analysis. PLoS One. 2012;7(3):e32482. doi: 10.1371/journal.pone.0032482
25. Burmen B, Modi S, Cavanaugh JS, et al. Tuberculosis screening outcomes for newly diagnosed persons living with HIV, Nyanza Province, Kenya, 2009. Int J Tuberc Lung Dis. 2016;20(1):79-84. doi: 10.5588/ijtld.15.0053
26. Зимина В.Н., Микова О.Е., Варецкая Т.А. и др. Выявление микобактерий туберкулеза в мокроте у больных ВИЧ-инфекцией при использовании современного алгоритма этиологической диагностики заболевания. Инфекционные болезни. 2018;16(1):28-34 [Zimina VN, Mikova OE, Varetskaya TA, et al. Detection of mycobacterium tuberculosis in sputum of patients with HIV infection using a modern algorithm of etiological diagnosis of disease. Infectious Diseases. 2018;16(1):28-34 (In Russ.)]. doi: 10.20953/1729-9225-2018-1-28-34
27. Kim SJ. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J. 2005;25(3):564-9. doi: 10.1183/09031936.05.00111304
28. Слогоцкая Л.В., Синицын М.В., Кудлай Д.А. Возможности иммунологических тестов в диагностике латентной туберкулезной инфекции и туберкулеза. Туберкулез и болезни легких. 2019;97(11):46-58 [Slogotskaya LV, Sinitsyn MV, Kudlay DA. Potentialities of immunological tests in the diagnosis of latent tuberculosis infection and tuberculosis. Tuberculosis and Lung Diseases. 2019;97(11):46-58 (In Russ.)]. doi: 10.21292/2075-1230-2019-97-11-46-58
29. Aichelburg MC, Rieger A, Breitenecker F, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis. 2009;48(7):954-62. doi: 10.1086/597351
30. WHO guidelines on tuberculosis infection prevention and control, 2019 update. World Health Organization, Geneva 2019. https://apps.who.int/iris/bitstream/handle/10665/311259/9789241550512-eng.pdf?ua=1
31. Савоненкова Л.Н., Рузов В.И., Колчин Д.В. и др. Трудности и ошибки диагностики абдоминального туберкулеза в практике терапевта. Терапевтический архив. 2019;91(11):16-9 [Savonenkova LN, Ruzov VI, Kolchin DV, et al. Difficulties and mistakes in the diagnosis of abdominal tuberculosis in the practice of the general practitioner.
Therapeutic Archive. 2019;91(11):16-9 (In Russ.)]. doi: 10.26442/00403660.2019.11.000374
32. Пантелеев А.М., Никулина О.В., Христусев А.С. и др. Дифференциальная диагностика туберкулеза и микобактериоза у больных ВИЧ-инфекцией. Туберкулез и болезни легких. 2017;95(10):47-52 [Panteleev AM, Nikulina OV, Khristusev AS, et al. Differential diagnostics of tuberculosis and mycobacteriosis in HIV patients. Tuberculosis and Lung Diseases. 2017;95(10):47-52 (In Russ.)]. doi: 10.21292/2075-1230-2017-95-10-47-52
33. Синицын М.В., Скопин М.С., Решетников М.Н. и др. Дифференциальная диагностика лимфаденопатии брюшной полости у больных ВИЧ-инфекцией. Туберкулез и болезни легких. 2019;97(2):5-11 [Sinitsyn MV, Skopin MS, Reshetnikov MN, et al. Differential diagnostics of abdomen lymphadenopathy in HIV patients. Tuberculosis and Lung Diseases. 2019;97(2):5-11 (In Russ.)]. doi: 10.21292/2075-1230-2019-97-2-5-11
34. Литвинов В.И., Макарова М.В., Краснова М.А. Нетуберкулезные микобактерии. М.: МНПЦБТ, 2008 [Litvinov VI, Makarova MV, Krasnova MA. Non-tuberculous mycobacteria. Moscow: MNPTsBT, 2008 (In Russ.)].
35. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167(4):603-62. doi: 10.1164/rccm.167.4.603
36. Centers for Disease Control and Prevention (CDC). Multidrug-resistant tuberculosis outbreak on an HIV ward-Madrid, Spain, 1991-1995. MMWR Morb Mortal Wkly Rep. 1996;45(16):330-3.
37. Туберкулез с множественной лекарственной устойчивостью. Под ред. И. Бастиан, Ф. Порталс. М.: Медицина и жизнь, 2003 [Multidrug-resistant tuberculosis. Pod red. I Bastian, F Portals. Moscow:
Meditsina i zhizn', 2003 (In Russ.)].
38. A guide to monitoring and evaluation for collaborative TB/HIV activities, 2015 revision. World Health Organization, Geneva 2015. http://www.who.int/tb/publications/monitoring-evaluation-collaborative-tb-hiv/en/
39. Hermans SM, Zinyakatira N, Caldwell J, et al. High rates of recurrent TB disease: a population-level cohort study. Clinical Infectious Diseases. 2020:ciaa470. doi: 10.1093/cid/ciaa470
40. Migliori GB, Zellweger JP, Abubakar I, et al. European union standards for tuberculosis care. Eur Respir J. 2012;39(4):807-19. doi: 10.1183/09031936.00203811
41. Marks SM, Mase SR, Morris SB. Systematic review, meta-analysis, and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrugresistant tuberculosis. Clin Infect Dis. 2017; 64(12):1670-7. doi: 10.1093/cid/cix208
42. Клинические рекомендации. Туберкулез у взрослых. Общероссийская общественная организация «Российское общество фтизиатров». Минздрав РФ, 2020 [Klinicheskie rekomendatsii. Tuberkulez u vzroslykh. Obshcherossiiskaya obshchestvennaya organizatsiya “Rossiiskoe obshchestvo ftiziatrov”. Minzdrav RF, 2020 (In Russ.)]. http://cr.rosminzdrav.ru/#!/recomend/943
43. WHO consolidated guidelines on drug-resistant tuberculosis treatment. World Health Organization, Geneva 2019. https://apps.who.int/iris/bitstream/handle/10665/311389/9789241550529-eng.pdf
44. Rapid communication: key changes to treatment of drug-resistant tuberculosis. World Health Organization, Geneva 2019. https://www.who.int/tb/publications/2019/WHO_RapidCommunicationMDR_TB2019.pdf?ua=1
45. Migliori GB, Tiberi S, Zumla A, et al. MDR/XDR-TB management of patients and contacts: challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. Int J Infect Dis. 2020;92(3):15-25. doi: 10.1016/j.ijid.2020.01.042
46. Uthman OA, Okwundu C, Gbenga K, et al. Optimal Timing of Antiretroviral Therapy Initiation for HIV-Infected Adults With Newly Diagnosed Pulmonary Tuberculosis: A Systematic Review and Meta-analysis. Ann Intern Med. 2015;163(1):32-9. doi: 10.7326/M14-2979
47. Borisov SE, Dheda K, Enwerem M, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR-and
XDR-TB: a multicentre study. Eur Respir J. 2017;49(5):1700387. doi: 10.1183/13993003.00387-2017
48. Calligaro G, Moodley L, Symons G, Dheda K. The medical and surgical treatment of drug-resistant tuberculosis. J Thora Dis. 2014;3(6):186-95. doi: 10.3978/j.issn.2072-1439.2013.11.11
49. Pontali E, Sotgiu G, D'Ambrosio L, et al. Bedaquiline and
multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. Eur Respir J. 2016;47(2):394-402. doi: 10.1183/13993003.01891-2015
50. Thwaites G, Fisher M, Hemingway C, et al. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect. 2009;59(3):167-87. doi: 10.1016/j.jinf.2009.06.011
51. Решетников М.Н., Скопин М.С., Синицын М.В. и др. Выбор хирургической тактики при перфоративных туберкулезных язвах кишечника у больных ВИЧ-инфекцией. Туберкулез и болезни легких. 2017;95(9):19-24 [Reshetnikov MN, Skopin MS, Sinitsyn MV, et al. The choice of surgical tactics in perforated tuberculous intestinal ulcers in HIV patients. Tuberculosis Lung Dis. 2017;95(9):19-24 (In Russ.)]. doi: 10.21292/2075-1230-2017-95-9-19-24
52. Akkerman O, Aleksa A, Alffenaar JW, et al. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study. Int J Infect Dis. 2019;83:72-6. doi: 10.1016/j.ijid.2019.03.036
53. Marrone MT, Venkataramanan V, Goodman M, et al. Surgical interventions for drug-resistant tuberculosis: A systematic review and meta-analysis. Int J Tuberc Lung Dis. 2013;17(1):6-16. doi: 10.5588/ijtld.12.0198
54. Kilani T, Boudaya MS, Zribi H, et al. Surgery for thoracic tuberculosis. Revue de Pneumologie Clinique. 2015;71(2-3):140-58. doi: 10.1016/j.pneumo.2014.03.005
55. Migliori GB, Ortmann J, Girardi E, et al. Extensively drug-resistant tuberculosis, Italy and Germany. Emerg Infect Dis. 2007;13(5):780-2. doi: 10.3201/eid1305.070200
56. Prasad R, Singh A, Balasubramanian V, Gupta N. Extensively drug-resistant tuberculosis in India: Current evidence on diagnosis & management. Indian J Med Res. 2017;145(3):271-93. doi: 10.4103/ijmr.IJMR_177_16
57. Rao M, Ippolito G, Mfinanga S, et al. Improving treatment outcomes for MDR-TB – Novel host-directed therapies and personalized
medicine of the future. Int J Infect Dis. 2019;3:62-7. doi: 10.1016/j.ijid.2019.01.039
58. Lange C, Aarnoutse RE, Alffenaar JWC, et al. Management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2019;23(6): 645-62. doi: 10.5588/ijtld.18.0622
59. Migliori GB, D’Ambrosio L, Centis R, et al. Guiding principles to reduce tuberculosis transmission in the WHO European region. World Health Organization Regional Office for Europe, Copenhagen 2018. http://www.euro.who.int/__data/assets/pdf_file/0008/377954/ic-principles-eng.pdf
2. Sotsial'no znachimye zabolevaniya naseleniya Rossii v 2018 godu (Statisticheskie materialy). Minzdrav RF, 2019 (In Russ.)
https://www.rosminzdrav.ru/ministry/61/22/stranitsa-979/statisticheskie-i-informatsionnye-materialy/...
3. Epidemiologicheskaia situatsiia po tuberkulezu v Rossii, 2018. TsNIIOIZ Minzdrava RF, 2019 (In Russ.) https://mednet.ru/images/materials/CMT/2018_god_tuberkulez_
epidsituaciya.pdf
4. Protivotuberkuleznaya rabota v gorode Moskve. Analiticheskii obzor statisticheskikh pokazatelei po tuberkulezu, 2018. Pod red. EM Bogorodskoi, VI Litvinova, EM Belilovskogo. Moscow: MNPTsBT, 2019 (In Russ.)
5. TB/VICh v Rossiiskoi Federatsii. Epidemiologiya, osobennosti klinicheskikh proyavlenii i rezul'taty lecheniya. Pod red. SA Sterlikova. Moscow: RIO TsNIIOIZ, 2017 (In Russ.)
6. Sinitsyn MV, Belilovsky EM, Sokolinа IA, et al. Extrapulmonary tuberculosis in HIV Patients. Tuberculosis and Lung Diseases. 2017;95(11):19-25 (In Russ.) doi: 10.21292/2075-1230-2017-95-11-19-25
7. Sacula A. Carlo Forlanini, inventor of artificial pneumothorax for treatment of pulmonary tuberculosis. Thorax. 1983;38:326-32. doi: 10.1136/thx.38.5.326
8. Jacobaeus HV. Ur die Moglichkeitdie Zystoskopie bei Untersuchung seroser Hohlungen anzuwenden. Munchener Medizinische Wochenschrift. 1910;57;2090-2.
9. Ghai SN. Extra pleural pneumonolysis with or without plombage in thoracoplasty failures: review of 21 cases. Indian J Tuberc. 1958;5(3):122-9.
10. Tiberi S, Torrico MM, Rahman A, et al. Managing severe tuberculosis and its sequelae: from intensive care to surgery and rehabilitation. J Brasileiro Pneumologia. 2019;45(2):e20180324. doi: 10.1590/1806-3713/e20180324
11. McDermott W, Muschenheim C, Hadley SD. Streptomycin in the treatment of tuberculosis in humans. J Clin Invest. 1947;26(6):1190.
12. Rabukhin AE. Respiratory tuberculosis in adults. Moscow: Meditsina, 1976 (In Russ.)
13. Khomenko AG. Chemotherapy for pulmonary tuberculosis. Moscow: Meditsina, 1980 (In Russ.)
14. Iseman MD, Sbarbaro JA. Short-course chemotherapy of tuberculosis. Hail Britannia (and friends)! Am Rev Respir Dis. 1991;(4 Pt 1):697-8. doi: 10.1164/ajrccm/143.4_Pt_1.697
15. Sensi P. History of the development of rifampin. Rev Infect Dis. 1983;5(Suppl. 3):S402-406. doi: 10.1093/clinids/5.supplement_3.s402
16. Styblo K. Recent advances in epidemiological research in tuberculosis. Advances in Tuberculosis Research. 1980;20:1-63.
17. Centers for Disease Control and Prevention (CDC). Pneumocystis pneumonia-Los Angeles. 1981. MMWR Morb Mortal Wkly Rep. 1996;45(34):729-33.
18. Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med. 1981;305(24):1425-31. doi: 10.1056/NEJM198112103052401
19. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;1:CD000171. doi: 10.1002/14651858.
CD000171.pub3
20. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2004;1:CD000171. doi: 10.1002/14651858.CD000171.pub2
21. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003;163(9):1009-21. doi: 10.1001/archinte.163.9.1009
22. Varghese GM, Janardhanan J, Ralph R, Abraham OC. The Twin Epidemics of Tuberculosis and HIV. Curr Infect Dis Rep. 2013;15:77-84. doi: 10.1007/s11908-012-0311-3
23. National Institute for Health and Clinical Excellence. Tuberculosis: Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London, 2016. https://www.nice.org.uk/guidance/ng33
24. Santin M, Muñoz L, Rigau D. Interferon-γ release assays for the diagnosis of tuberculosis and tuberculosis infection in HIV-infected adults: a systematic review and meta-analysis. PLoS One. 2012;7(3):e32482. doi: 10.1371/journal.pone.0032482
25. Burmen B, Modi S, Cavanaugh JS, et al. Tuberculosis screening outcomes for newly diagnosed persons living with HIV, Nyanza Province, Kenya, 2009. Int J Tuberc Lung Dis. 2016;20(1):79-84. doi: 10.5588/ijtld.15.0053
26. Zimina VN, Mikova OE, Varetskaya TA, et al. Detection of mycobacterium tuberculosis in sputum of patients with HIV infection using a modern algorithm of etiological diagnosis of disease. Infectious Diseases. 2018;16(1):28-34 (In Russ.) doi: 10.20953/1729-9225-2018-1-28-34
27. Kim SJ. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J. 2005;25(3):564-9. doi: 10.1183/09031936.05.00111304
28. Slogotskaya LV, Sinitsyn MV, Kudlay DA. Potentialities of immunological tests in the diagnosis of latent tuberculosis infection and tuberculosis. Tuberculosis and Lung Diseases. 2019;97(11):46-58 (In Russ.) doi: 10.21292/2075-1230-2019-97-11-46-58
29. Aichelburg MC, Rieger A, Breitenecker F, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis. 2009;48(7):954-62. doi: 10.1086/597351
30. WHO guidelines on tuberculosis infection prevention and control, 2019 update. World Health Organization, Geneva 2019. https://apps.who.int/iris/bitstream/handle/10665/311259/9789241550512-eng.pdf?ua=1
31. Savonenkova LN, Ruzov VI, Kolchin DV, et al. Difficulties and mistakes in the diagnosis of abdominal tuberculosis in the practice of the general practitioner.
Therapeutic Archive. 2019;91(11):16-9 (In Russ.)
doi:10.26442/00403660.2019.11.000374
32. Panteleev AM, Nikulina OV, Khristusev AS, et al. Differential diagnostics of tuberculosis and mycobacteriosis in HIV patients. Tuberculosis and Lung Diseases. 2017;95(10):47-52 (In Russ.) doi: 10.21292/2075-1230-2017-95-10-47-52
33. Sinitsyn MV, Skopin MS, Reshetnikov MN, et al. Differential diagnostics of abdomen lymphadenopathy in HIV patients. Tuberculosis and Lung Diseases. 2019;97(2):5-11 (In Russ.) doi: 10.21292/2075-1230-2019-97-2-5-11
34. Litvinov VI, Makarova MV, Krasnova MA. Non-tuberculous mycobacteria. Moscow: MNPTsBT, 2008 (In Russ.)
35. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167(4):603-62. doi: 10.1164/rccm.167.4.603
36. Centers for Disease Control and Prevention (CDC). Multidrug-resistant tuberculosis outbreak on an HIV ward-Madrid, Spain, 1991-1995. MMWR Morb Mortal Wkly Rep. 1996;45(16):330-3.
37. Multidrug-resistant tuberculosis. Pod red. I Bastian, F Portals. Moscow:
Meditsina i zhizn', 2003 (In Russ.)
38. A guide to monitoring and evaluation for collaborative TB/HIV activities, 2015 revision. World Health Organization, Geneva 2015. http://www.who.int/tb/publications/monitoring-evaluation-collaborative-tb-hiv/en/
39. Hermans SM, Zinyakatira N, Caldwell J, et al. High rates of recurrent TB disease: a population-level cohort study. Clinical Infectious Diseases. 2020:ciaa470. doi: 10.1093/cid/ciaa470
40. Migliori GB, Zellweger JP, Abubakar I, et al. European union standards for tuberculosis care. Eur Respir J. 2012;39(4):807-19. doi: 10.1183/09031936.00203811
41. Marks SM, Mase SR, Morris SB. Systematic review, meta-analysis, and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrugresistant tuberculosis. Clin Infect Dis. 2017; 64(12):1670-7. doi: 10.1093/cid/cix208
42. Klinicheskie rekomendatsii. Tuberkulez u vzroslykh. Obshcherossiiskaya obshchestvennaya organizatsiya “Rossiiskoe obshchestvo ftiziatrov”. Minzdrav RF, 2020 (In Russ.) http://cr.rosminzdrav.ru/#!/recomend/943
43. WHO consolidated guidelines on drug-resistant tuberculosis treatment. World Health Organization, Geneva 2019. https://apps.who.int/iris/bitstream/handle/10665/311389/9789241550529-eng.pdf
44. Rapid communication: key changes to treatment of drug-resistant tuberculosis. World Health Organization, Geneva 2019. https://www.who.int/tb/publications/2019/WHO_RapidCommunicationMDR_TB2019.pdf?ua=1
45. Migliori GB, Tiberi S, Zumla A, et al. MDR/XDR-TB management of patients and contacts: challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. Int J Infect Dis. 2020;92(3):15-25. doi: 10.1016/j.ijid.2020.01.042
46. Uthman OA, Okwundu C, Gbenga K, et al. Optimal Timing of Antiretroviral Therapy Initiation for HIV-Infected Adults With Newly Diagnosed Pulmonary Tuberculosis: A Systematic Review and Meta-analysis. Ann Intern Med. 2015;163(1):32-9. doi: 10.7326/M14-2979
47. Borisov SE, Dheda K, Enwerem M, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR-and
XDR-TB: a multicentre study. Eur Respir J. 2017;49(5):1700387. doi: 10.1183/13993003.00387-2017
48. Calligaro G, Moodley L, Symons G, Dheda K. The medical and surgical treatment of drug-resistant tuberculosis. J Thora Dis. 2014;3(6):186-95. doi: 10.3978/j.issn.2072-1439.2013.11.11
49. Pontali E, Sotgiu G, D'Ambrosio L, et al. Bedaquiline and
multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. Eur Respir J. 2016;47(2):394-402. doi: 10.1183/13993003.01891-2015
50. Thwaites G, Fisher M, Hemingway C, et al. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect. 2009;59(3):167-87. doi: 10.1016/j.jinf.2009.06.011
51. Reshetnikov MN, Skopin MS, Sinitsyn MV, et al. The choice of surgical tactics in perforated tuberculous intestinal ulcers in HIV patients. Tuberculosis Lung Dis. 2017;95(9):19-24 (In Russ.) doi: 10.21292/2075-1230-2017-95-9-19-24
52. Akkerman O, Aleksa A, Alffenaar JW, et al. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study. Int J Infect Dis. 2019;83:72-6. doi: 10.1016/j.ijid.2019.03.036
53. Marrone MT, Venkataramanan V, Goodman M, et al. Surgical interventions for drug-resistant tuberculosis: A systematic review and meta-analysis. Int J Tuberc Lung Dis. 2013;17(1):6-16. doi: 10.5588/ijtld.12.0198
54. Kilani T, Boudaya MS, Zribi H, et al. Surgery for thoracic tuberculosis. Revue de Pneumologie Clinique. 2015;71(2-3):140-58. doi: 10.1016/j.pneumo.2014.03.005
55. Migliori GB, Ortmann J, Girardi E, et al. Extensively drug-resistant tuberculosis, Italy and Germany. Emerg Infect Dis. 2007;13(5):780-2. doi: 10.3201/eid1305.070200
56. Prasad R, Singh A, Balasubramanian V, Gupta N. Extensively drug-resistant tuberculosis in India: Current evidence on diagnosis & management. Indian J Med Res. 2017;145(3):271-93. doi: 10.4103/ijmr.IJMR_177_16
57. Rao M, Ippolito G, Mfinanga S, et al. Improving treatment outcomes for MDR-TB – Novel host-directed therapies and personalized
medicine of the future. Int J Infect Dis. 2019;3:62-7. doi: 10.1016/j.ijid.2019.01.039
58. Lange C, Aarnoutse RE, Alffenaar JWC, et al. Management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2019;23(6): 645-62. doi: 10.5588/ijtld.18.0622
59. Migliori GB, D’Ambrosio L, Centis R, et al. Guiding principles to reduce tuberculosis transmission in the WHO European region. World Health Organization Regional Office for Europe, Copenhagen 2018. http://www.euro.who.int/__data/assets/pdf_file/0008/377954/ic-principles-eng.pdf
2. Социально значимые заболевания населения России в 2018 году. Статистические материалы. Минздрав РФ, 2019 [Sotsial'no znachimye zabolevaniya naseleniya Rossii v 2018 godu (Statisticheskie materialy). Minzdrav RF, 2019 (In Russ.)]. https://www.rosminzdrav.ru/ministry/61/22/stranitsa-979/statisticheskie-i-informatsionnye-materialy/...
3. Эпидемиологическая ситуация по туберкулезу в России, 2018. ЦНИИОИЗ Минздрава РФ, 2019 [Epidemiologicheskaia situatsiia po tuberkulezu v Rossii, 2018. TsNIIOIZ Minzdrava RF, 2019 (In Russ.)]. https://mednet.ru/images/materials/CMT/2018_god_tuberkulez_
epidsituaciya.pdf
4. Противотуберкулезная работа в городе Москве. Аналитический обзор статистических показателей по туберкулезу, 2018. Под ред. Е.М. Богородской, В.И. Литвинова, Е.М. Белиловского. М.: МНПЦБТ, 2019 [Protivotuberkuleznaya rabota v gorode Moskve. Analiticheskii obzor statisticheskikh pokazatelei po tuberkulezu, 2018. Pod red. EM Bogorodskoi, VI Litvinova, EM Belilovskogo. Moscow: MNPTsBT, 2019 (In Russ.)].
5. ТБ/ВИЧ в Российской Федерации. Эпидемиология, особенности клинических проявлений и результаты лечения. Под ред. С.А. Стерликова. М.: РИО ЦНИИОИЗ, 2017 [TB/VICh v Rossiiskoi Federatsii. Epidemiologiya, osobennosti klinicheskikh proyavlenii i rezul'taty lecheniya. Pod red. SA Sterlikova. Moscow: RIO TsNIIOIZ, 2017 (In Russ.)].
6. Синицын М.В., Белиловский Е.М., Соколина И.А. и др. Внелегочные локализации туберкулеза у больных ВИЧ-инфекцией. Туберкулез и болезни легких. 2017;95(11):19-25. [Sinitsyn MV, Belilovsky EM, Sokolinа IA, et al. Extrapulmonary tuberculosis in HIV Patients. Tuberculosis and Lung Diseases. 2017;95(11):19-25 (In Russ.)]. doi: 10.21292/2075-1230-2017-95-11-19-25
7. Sacula A. Carlo Forlanini, inventor of artificial pneumothorax for treatment of pulmonary tuberculosis. Thorax. 1983;38:326-32. doi: 10.1136/thx.38.5.326
8. Jacobaeus HV. Ur die Moglichkeitdie Zystoskopie bei Untersuchung seroser Hohlungen anzuwenden. Munchener Medizinische Wochenschrift. 1910;57;2090-2.
9. Ghai SN. Extra pleural pneumonolysis with or without plombage in thoracoplasty failures: review of 21 cases. Indian J Tuberc. 1958;5(3):122-9.
10. Tiberi S, Torrico MM, Rahman A, et al. Managing severe tuberculosis and its sequelae: from intensive care to surgery and rehabilitation. J Brasileiro Pneumologia. 2019;45(2):e20180324. doi: 10.1590/1806-3713/e20180324
11. McDermott W, Muschenheim C, Hadley SD. Streptomycin in the treatment of tuberculosis in humans. J Clin Invest. 1947;26(6):1190.
12. Рабухин А.Е. Туберкулез органов дыхания у взрослых. М.: Медицина, 1976 [Rabukhin AE. Respiratory tuberculosis in adults. Moscow: Meditsina, 1976 (In Russ.)].
13. Хоменко А.Г. Химиотерапия туберкулеза легких. М.: Медицина, 1980 [Khomenko AG. Chemotherapy for pulmonary tuberculosis. Moscow: Meditsina, 1980 (In Russ.)].
14. Iseman MD, Sbarbaro JA. Short-course chemotherapy of tuberculosis. Hail Britannia (and friends)! Am Rev Respir Dis. 1991;(4 Pt 1):697-8. doi: 10.1164/ajrccm/143.4_Pt_1.697
15. Sensi P. History of the development of rifampin. Rev Infect Dis. 1983;5(Suppl. 3):S402-406. doi: 10.1093/clinids/5.supplement_3.s402
16. Styblo K. Recent advances in epidemiological research in tuberculosis. Advances in Tuberculosis Research. 1980;20:1-63.
17. Centers for Disease Control and Prevention (CDC). Pneumocystis pneumonia-Los Angeles. 1981. MMWR Morb Mortal Wkly Rep. 1996;45(34):729-33.
18. Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med. 1981;305(24):1425-31. doi: 10.1056/NEJM198112103052401
19. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;1:CD000171. doi: 10.1002/14651858.
CD000171.pub3
20. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2004;1:CD000171. doi: 10.1002/14651858.CD000171.pub2
21. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003;163(9):1009-21. doi: 10.1001/archinte.163.9.1009
22. Varghese GM, Janardhanan J, Ralph R, Abraham OC. The Twin Epidemics of Tuberculosis and HIV. Curr Infect Dis Rep. 2013;15:77-84. doi: 10.1007/s11908-012-0311-3
23. National Institute for Health and Clinical Excellence. Tuberculosis: Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London, 2016. https://www.nice.org.uk/guidance/ng33
24. Santin M, Muñoz L, Rigau D. Interferon-γ release assays for the diagnosis of tuberculosis and tuberculosis infection in HIV-infected adults: a systematic review and meta-analysis. PLoS One. 2012;7(3):e32482. doi: 10.1371/journal.pone.0032482
25. Burmen B, Modi S, Cavanaugh JS, et al. Tuberculosis screening outcomes for newly diagnosed persons living with HIV, Nyanza Province, Kenya, 2009. Int J Tuberc Lung Dis. 2016;20(1):79-84. doi: 10.5588/ijtld.15.0053
26. Зимина В.Н., Микова О.Е., Варецкая Т.А. и др. Выявление микобактерий туберкулеза в мокроте у больных ВИЧ-инфекцией при использовании современного алгоритма этиологической диагностики заболевания. Инфекционные болезни. 2018;16(1):28-34 [Zimina VN, Mikova OE, Varetskaya TA, et al. Detection of mycobacterium tuberculosis in sputum of patients with HIV infection using a modern algorithm of etiological diagnosis of disease. Infectious Diseases. 2018;16(1):28-34 (In Russ.)]. doi: 10.20953/1729-9225-2018-1-28-34
27. Kim SJ. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J. 2005;25(3):564-9. doi: 10.1183/09031936.05.00111304
28. Слогоцкая Л.В., Синицын М.В., Кудлай Д.А. Возможности иммунологических тестов в диагностике латентной туберкулезной инфекции и туберкулеза. Туберкулез и болезни легких. 2019;97(11):46-58 [Slogotskaya LV, Sinitsyn MV, Kudlay DA. Potentialities of immunological tests in the diagnosis of latent tuberculosis infection and tuberculosis. Tuberculosis and Lung Diseases. 2019;97(11):46-58 (In Russ.)]. doi: 10.21292/2075-1230-2019-97-11-46-58
29. Aichelburg MC, Rieger A, Breitenecker F, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis. 2009;48(7):954-62. doi: 10.1086/597351
30. WHO guidelines on tuberculosis infection prevention and control, 2019 update. World Health Organization, Geneva 2019. https://apps.who.int/iris/bitstream/handle/10665/311259/9789241550512-eng.pdf?ua=1
31. Савоненкова Л.Н., Рузов В.И., Колчин Д.В. и др. Трудности и ошибки диагностики абдоминального туберкулеза в практике терапевта. Терапевтический архив. 2019;91(11):16-9 [Savonenkova LN, Ruzov VI, Kolchin DV, et al. Difficulties and mistakes in the diagnosis of abdominal tuberculosis in the practice of the general practitioner.
Therapeutic Archive. 2019;91(11):16-9 (In Russ.)]. doi: 10.26442/00403660.2019.11.000374
32. Пантелеев А.М., Никулина О.В., Христусев А.С. и др. Дифференциальная диагностика туберкулеза и микобактериоза у больных ВИЧ-инфекцией. Туберкулез и болезни легких. 2017;95(10):47-52 [Panteleev AM, Nikulina OV, Khristusev AS, et al. Differential diagnostics of tuberculosis and mycobacteriosis in HIV patients. Tuberculosis and Lung Diseases. 2017;95(10):47-52 (In Russ.)]. doi: 10.21292/2075-1230-2017-95-10-47-52
33. Синицын М.В., Скопин М.С., Решетников М.Н. и др. Дифференциальная диагностика лимфаденопатии брюшной полости у больных ВИЧ-инфекцией. Туберкулез и болезни легких. 2019;97(2):5-11 [Sinitsyn MV, Skopin MS, Reshetnikov MN, et al. Differential diagnostics of abdomen lymphadenopathy in HIV patients. Tuberculosis and Lung Diseases. 2019;97(2):5-11 (In Russ.)]. doi: 10.21292/2075-1230-2019-97-2-5-11
34. Литвинов В.И., Макарова М.В., Краснова М.А. Нетуберкулезные микобактерии. М.: МНПЦБТ, 2008 [Litvinov VI, Makarova MV, Krasnova MA. Non-tuberculous mycobacteria. Moscow: MNPTsBT, 2008 (In Russ.)].
35. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167(4):603-62. doi: 10.1164/rccm.167.4.603
36. Centers for Disease Control and Prevention (CDC). Multidrug-resistant tuberculosis outbreak on an HIV ward-Madrid, Spain, 1991-1995. MMWR Morb Mortal Wkly Rep. 1996;45(16):330-3.
37. Туберкулез с множественной лекарственной устойчивостью. Под ред. И. Бастиан, Ф. Порталс. М.: Медицина и жизнь, 2003 [Multidrug-resistant tuberculosis. Pod red. I Bastian, F Portals. Moscow:
Meditsina i zhizn', 2003 (In Russ.)].
38. A guide to monitoring and evaluation for collaborative TB/HIV activities, 2015 revision. World Health Organization, Geneva 2015. http://www.who.int/tb/publications/monitoring-evaluation-collaborative-tb-hiv/en/
39. Hermans SM, Zinyakatira N, Caldwell J, et al. High rates of recurrent TB disease: a population-level cohort study. Clinical Infectious Diseases. 2020:ciaa470. doi: 10.1093/cid/ciaa470
40. Migliori GB, Zellweger JP, Abubakar I, et al. European union standards for tuberculosis care. Eur Respir J. 2012;39(4):807-19. doi: 10.1183/09031936.00203811
41. Marks SM, Mase SR, Morris SB. Systematic review, meta-analysis, and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrugresistant tuberculosis. Clin Infect Dis. 2017; 64(12):1670-7. doi: 10.1093/cid/cix208
42. Клинические рекомендации. Туберкулез у взрослых. Общероссийская общественная организация «Российское общество фтизиатров». Минздрав РФ, 2020 [Klinicheskie rekomendatsii. Tuberkulez u vzroslykh. Obshcherossiiskaya obshchestvennaya organizatsiya “Rossiiskoe obshchestvo ftiziatrov”. Minzdrav RF, 2020 (In Russ.)]. http://cr.rosminzdrav.ru/#!/recomend/943
43. WHO consolidated guidelines on drug-resistant tuberculosis treatment. World Health Organization, Geneva 2019. https://apps.who.int/iris/bitstream/handle/10665/311389/9789241550529-eng.pdf
44. Rapid communication: key changes to treatment of drug-resistant tuberculosis. World Health Organization, Geneva 2019. https://www.who.int/tb/publications/2019/WHO_RapidCommunicationMDR_TB2019.pdf?ua=1
45. Migliori GB, Tiberi S, Zumla A, et al. MDR/XDR-TB management of patients and contacts: challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. Int J Infect Dis. 2020;92(3):15-25. doi: 10.1016/j.ijid.2020.01.042
46. Uthman OA, Okwundu C, Gbenga K, et al. Optimal Timing of Antiretroviral Therapy Initiation for HIV-Infected Adults With Newly Diagnosed Pulmonary Tuberculosis: A Systematic Review and Meta-analysis. Ann Intern Med. 2015;163(1):32-9. doi: 10.7326/M14-2979
47. Borisov SE, Dheda K, Enwerem M, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR-and
XDR-TB: a multicentre study. Eur Respir J. 2017;49(5):1700387. doi: 10.1183/13993003.00387-2017
48. Calligaro G, Moodley L, Symons G, Dheda K. The medical and surgical treatment of drug-resistant tuberculosis. J Thora Dis. 2014;3(6):186-95. doi: 10.3978/j.issn.2072-1439.2013.11.11
49. Pontali E, Sotgiu G, D'Ambrosio L, et al. Bedaquiline and
multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. Eur Respir J. 2016;47(2):394-402. doi: 10.1183/13993003.01891-2015
50. Thwaites G, Fisher M, Hemingway C, et al. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect. 2009;59(3):167-87. doi: 10.1016/j.jinf.2009.06.011
51. Решетников М.Н., Скопин М.С., Синицын М.В. и др. Выбор хирургической тактики при перфоративных туберкулезных язвах кишечника у больных ВИЧ-инфекцией. Туберкулез и болезни легких. 2017;95(9):19-24 [Reshetnikov MN, Skopin MS, Sinitsyn MV, et al. The choice of surgical tactics in perforated tuberculous intestinal ulcers in HIV patients. Tuberculosis Lung Dis. 2017;95(9):19-24 (In Russ.)]. doi: 10.21292/2075-1230-2017-95-9-19-24
52. Akkerman O, Aleksa A, Alffenaar JW, et al. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study. Int J Infect Dis. 2019;83:72-6. doi: 10.1016/j.ijid.2019.03.036
53. Marrone MT, Venkataramanan V, Goodman M, et al. Surgical interventions for drug-resistant tuberculosis: A systematic review and meta-analysis. Int J Tuberc Lung Dis. 2013;17(1):6-16. doi: 10.5588/ijtld.12.0198
54. Kilani T, Boudaya MS, Zribi H, et al. Surgery for thoracic tuberculosis. Revue de Pneumologie Clinique. 2015;71(2-3):140-58. doi: 10.1016/j.pneumo.2014.03.005
55. Migliori GB, Ortmann J, Girardi E, et al. Extensively drug-resistant tuberculosis, Italy and Germany. Emerg Infect Dis. 2007;13(5):780-2. doi: 10.3201/eid1305.070200
56. Prasad R, Singh A, Balasubramanian V, Gupta N. Extensively drug-resistant tuberculosis in India: Current evidence on diagnosis & management. Indian J Med Res. 2017;145(3):271-93. doi: 10.4103/ijmr.IJMR_177_16
57. Rao M, Ippolito G, Mfinanga S, et al. Improving treatment outcomes for MDR-TB – Novel host-directed therapies and personalized
medicine of the future. Int J Infect Dis. 2019;3:62-7. doi: 10.1016/j.ijid.2019.01.039
58. Lange C, Aarnoutse RE, Alffenaar JWC, et al. Management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2019;23(6): 645-62. doi: 10.5588/ijtld.18.0622
59. Migliori GB, D’Ambrosio L, Centis R, et al. Guiding principles to reduce tuberculosis transmission in the WHO European region. World Health Organization Regional Office for Europe, Copenhagen 2018. http://www.euro.who.int/__data/assets/pdf_file/0008/377954/ic-principles-eng.pdf
________________________________________________
2. Sotsial'no znachimye zabolevaniya naseleniya Rossii v 2018 godu (Statisticheskie materialy). Minzdrav RF, 2019 (In Russ.)
https://www.rosminzdrav.ru/ministry/61/22/stranitsa-979/statisticheskie-i-informatsionnye-materialy/...
3. Epidemiologicheskaia situatsiia po tuberkulezu v Rossii, 2018. TsNIIOIZ Minzdrava RF, 2019 (In Russ.) https://mednet.ru/images/materials/CMT/2018_god_tuberkulez_
epidsituaciya.pdf
4. Protivotuberkuleznaya rabota v gorode Moskve. Analiticheskii obzor statisticheskikh pokazatelei po tuberkulezu, 2018. Pod red. EM Bogorodskoi, VI Litvinova, EM Belilovskogo. Moscow: MNPTsBT, 2019 (In Russ.)
5. TB/VICh v Rossiiskoi Federatsii. Epidemiologiya, osobennosti klinicheskikh proyavlenii i rezul'taty lecheniya. Pod red. SA Sterlikova. Moscow: RIO TsNIIOIZ, 2017 (In Russ.)
6. Sinitsyn MV, Belilovsky EM, Sokolinа IA, et al. Extrapulmonary tuberculosis in HIV Patients. Tuberculosis and Lung Diseases. 2017;95(11):19-25 (In Russ.) doi: 10.21292/2075-1230-2017-95-11-19-25
7. Sacula A. Carlo Forlanini, inventor of artificial pneumothorax for treatment of pulmonary tuberculosis. Thorax. 1983;38:326-32. doi: 10.1136/thx.38.5.326
8. Jacobaeus HV. Ur die Moglichkeitdie Zystoskopie bei Untersuchung seroser Hohlungen anzuwenden. Munchener Medizinische Wochenschrift. 1910;57;2090-2.
9. Ghai SN. Extra pleural pneumonolysis with or without plombage in thoracoplasty failures: review of 21 cases. Indian J Tuberc. 1958;5(3):122-9.
10. Tiberi S, Torrico MM, Rahman A, et al. Managing severe tuberculosis and its sequelae: from intensive care to surgery and rehabilitation. J Brasileiro Pneumologia. 2019;45(2):e20180324. doi: 10.1590/1806-3713/e20180324
11. McDermott W, Muschenheim C, Hadley SD. Streptomycin in the treatment of tuberculosis in humans. J Clin Invest. 1947;26(6):1190.
12. Rabukhin AE. Respiratory tuberculosis in adults. Moscow: Meditsina, 1976 (In Russ.)
13. Khomenko AG. Chemotherapy for pulmonary tuberculosis. Moscow: Meditsina, 1980 (In Russ.)
14. Iseman MD, Sbarbaro JA. Short-course chemotherapy of tuberculosis. Hail Britannia (and friends)! Am Rev Respir Dis. 1991;(4 Pt 1):697-8. doi: 10.1164/ajrccm/143.4_Pt_1.697
15. Sensi P. History of the development of rifampin. Rev Infect Dis. 1983;5(Suppl. 3):S402-406. doi: 10.1093/clinids/5.supplement_3.s402
16. Styblo K. Recent advances in epidemiological research in tuberculosis. Advances in Tuberculosis Research. 1980;20:1-63.
17. Centers for Disease Control and Prevention (CDC). Pneumocystis pneumonia-Los Angeles. 1981. MMWR Morb Mortal Wkly Rep. 1996;45(34):729-33.
18. Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med. 1981;305(24):1425-31. doi: 10.1056/NEJM198112103052401
19. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;1:CD000171. doi: 10.1002/14651858.
CD000171.pub3
20. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2004;1:CD000171. doi: 10.1002/14651858.CD000171.pub2
21. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med. 2003;163(9):1009-21. doi: 10.1001/archinte.163.9.1009
22. Varghese GM, Janardhanan J, Ralph R, Abraham OC. The Twin Epidemics of Tuberculosis and HIV. Curr Infect Dis Rep. 2013;15:77-84. doi: 10.1007/s11908-012-0311-3
23. National Institute for Health and Clinical Excellence. Tuberculosis: Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London, 2016. https://www.nice.org.uk/guidance/ng33
24. Santin M, Muñoz L, Rigau D. Interferon-γ release assays for the diagnosis of tuberculosis and tuberculosis infection in HIV-infected adults: a systematic review and meta-analysis. PLoS One. 2012;7(3):e32482. doi: 10.1371/journal.pone.0032482
25. Burmen B, Modi S, Cavanaugh JS, et al. Tuberculosis screening outcomes for newly diagnosed persons living with HIV, Nyanza Province, Kenya, 2009. Int J Tuberc Lung Dis. 2016;20(1):79-84. doi: 10.5588/ijtld.15.0053
26. Zimina VN, Mikova OE, Varetskaya TA, et al. Detection of mycobacterium tuberculosis in sputum of patients with HIV infection using a modern algorithm of etiological diagnosis of disease. Infectious Diseases. 2018;16(1):28-34 (In Russ.) doi: 10.20953/1729-9225-2018-1-28-34
27. Kim SJ. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J. 2005;25(3):564-9. doi: 10.1183/09031936.05.00111304
28. Slogotskaya LV, Sinitsyn MV, Kudlay DA. Potentialities of immunological tests in the diagnosis of latent tuberculosis infection and tuberculosis. Tuberculosis and Lung Diseases. 2019;97(11):46-58 (In Russ.) doi: 10.21292/2075-1230-2019-97-11-46-58
29. Aichelburg MC, Rieger A, Breitenecker F, et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis. 2009;48(7):954-62. doi: 10.1086/597351
30. WHO guidelines on tuberculosis infection prevention and control, 2019 update. World Health Organization, Geneva 2019. https://apps.who.int/iris/bitstream/handle/10665/311259/9789241550512-eng.pdf?ua=1
31. Savonenkova LN, Ruzov VI, Kolchin DV, et al. Difficulties and mistakes in the diagnosis of abdominal tuberculosis in the practice of the general practitioner.
Therapeutic Archive. 2019;91(11):16-9 (In Russ.)
doi:10.26442/00403660.2019.11.000374
32. Panteleev AM, Nikulina OV, Khristusev AS, et al. Differential diagnostics of tuberculosis and mycobacteriosis in HIV patients. Tuberculosis and Lung Diseases. 2017;95(10):47-52 (In Russ.) doi: 10.21292/2075-1230-2017-95-10-47-52
33. Sinitsyn MV, Skopin MS, Reshetnikov MN, et al. Differential diagnostics of abdomen lymphadenopathy in HIV patients. Tuberculosis and Lung Diseases. 2019;97(2):5-11 (In Russ.) doi: 10.21292/2075-1230-2019-97-2-5-11
34. Litvinov VI, Makarova MV, Krasnova MA. Non-tuberculous mycobacteria. Moscow: MNPTsBT, 2008 (In Russ.)
35. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167(4):603-62. doi: 10.1164/rccm.167.4.603
36. Centers for Disease Control and Prevention (CDC). Multidrug-resistant tuberculosis outbreak on an HIV ward-Madrid, Spain, 1991-1995. MMWR Morb Mortal Wkly Rep. 1996;45(16):330-3.
37. Multidrug-resistant tuberculosis. Pod red. I Bastian, F Portals. Moscow:
Meditsina i zhizn', 2003 (In Russ.)
38. A guide to monitoring and evaluation for collaborative TB/HIV activities, 2015 revision. World Health Organization, Geneva 2015. http://www.who.int/tb/publications/monitoring-evaluation-collaborative-tb-hiv/en/
39. Hermans SM, Zinyakatira N, Caldwell J, et al. High rates of recurrent TB disease: a population-level cohort study. Clinical Infectious Diseases. 2020:ciaa470. doi: 10.1093/cid/ciaa470
40. Migliori GB, Zellweger JP, Abubakar I, et al. European union standards for tuberculosis care. Eur Respir J. 2012;39(4):807-19. doi: 10.1183/09031936.00203811
41. Marks SM, Mase SR, Morris SB. Systematic review, meta-analysis, and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrugresistant tuberculosis. Clin Infect Dis. 2017; 64(12):1670-7. doi: 10.1093/cid/cix208
42. Klinicheskie rekomendatsii. Tuberkulez u vzroslykh. Obshcherossiiskaya obshchestvennaya organizatsiya “Rossiiskoe obshchestvo ftiziatrov”. Minzdrav RF, 2020 (In Russ.) http://cr.rosminzdrav.ru/#!/recomend/943
43. WHO consolidated guidelines on drug-resistant tuberculosis treatment. World Health Organization, Geneva 2019. https://apps.who.int/iris/bitstream/handle/10665/311389/9789241550529-eng.pdf
44. Rapid communication: key changes to treatment of drug-resistant tuberculosis. World Health Organization, Geneva 2019. https://www.who.int/tb/publications/2019/WHO_RapidCommunicationMDR_TB2019.pdf?ua=1
45. Migliori GB, Tiberi S, Zumla A, et al. MDR/XDR-TB management of patients and contacts: challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. Int J Infect Dis. 2020;92(3):15-25. doi: 10.1016/j.ijid.2020.01.042
46. Uthman OA, Okwundu C, Gbenga K, et al. Optimal Timing of Antiretroviral Therapy Initiation for HIV-Infected Adults With Newly Diagnosed Pulmonary Tuberculosis: A Systematic Review and Meta-analysis. Ann Intern Med. 2015;163(1):32-9. doi: 10.7326/M14-2979
47. Borisov SE, Dheda K, Enwerem M, et al. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR-and
XDR-TB: a multicentre study. Eur Respir J. 2017;49(5):1700387. doi: 10.1183/13993003.00387-2017
48. Calligaro G, Moodley L, Symons G, Dheda K. The medical and surgical treatment of drug-resistant tuberculosis. J Thora Dis. 2014;3(6):186-95. doi: 10.3978/j.issn.2072-1439.2013.11.11
49. Pontali E, Sotgiu G, D'Ambrosio L, et al. Bedaquiline and
multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. Eur Respir J. 2016;47(2):394-402. doi: 10.1183/13993003.01891-2015
50. Thwaites G, Fisher M, Hemingway C, et al. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect. 2009;59(3):167-87. doi: 10.1016/j.jinf.2009.06.011
51. Reshetnikov MN, Skopin MS, Sinitsyn MV, et al. The choice of surgical tactics in perforated tuberculous intestinal ulcers in HIV patients. Tuberculosis Lung Dis. 2017;95(9):19-24 (In Russ.) doi: 10.21292/2075-1230-2017-95-9-19-24
52. Akkerman O, Aleksa A, Alffenaar JW, et al. Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study. Int J Infect Dis. 2019;83:72-6. doi: 10.1016/j.ijid.2019.03.036
53. Marrone MT, Venkataramanan V, Goodman M, et al. Surgical interventions for drug-resistant tuberculosis: A systematic review and meta-analysis. Int J Tuberc Lung Dis. 2013;17(1):6-16. doi: 10.5588/ijtld.12.0198
54. Kilani T, Boudaya MS, Zribi H, et al. Surgery for thoracic tuberculosis. Revue de Pneumologie Clinique. 2015;71(2-3):140-58. doi: 10.1016/j.pneumo.2014.03.005
55. Migliori GB, Ortmann J, Girardi E, et al. Extensively drug-resistant tuberculosis, Italy and Germany. Emerg Infect Dis. 2007;13(5):780-2. doi: 10.3201/eid1305.070200
56. Prasad R, Singh A, Balasubramanian V, Gupta N. Extensively drug-resistant tuberculosis in India: Current evidence on diagnosis & management. Indian J Med Res. 2017;145(3):271-93. doi: 10.4103/ijmr.IJMR_177_16
57. Rao M, Ippolito G, Mfinanga S, et al. Improving treatment outcomes for MDR-TB – Novel host-directed therapies and personalized
medicine of the future. Int J Infect Dis. 2019;3:62-7. doi: 10.1016/j.ijid.2019.01.039
58. Lange C, Aarnoutse RE, Alffenaar JWC, et al. Management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2019;23(6): 645-62. doi: 10.5588/ijtld.18.0622
59. Migliori GB, D’Ambrosio L, Centis R, et al. Guiding principles to reduce tuberculosis transmission in the WHO European region. World Health Organization Regional Office for Europe, Copenhagen 2018. http://www.euro.who.int/__data/assets/pdf_file/0008/377954/ic-principles-eng.pdf
Авторы
М.В. Синицын, М.В. Калинина, Е.М. Белиловский, А.С. Галстян, М.Н. Решетников, Д.В. Плоткин
ГБУЗ «Московский научно-практический центр борьбы с туберкулезом» Департамента здравоохранения г. Москвы, Москва, Россия
Moscow Research and Clinical Center for Tuberculosis Control, Moscow, Russia
ГБУЗ «Московский научно-практический центр борьбы с туберкулезом» Департамента здравоохранения г. Москвы, Москва, Россия
________________________________________________
Moscow Research and Clinical Center for Tuberculosis Control, Moscow, Russia
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.